Prime Medicine (PRME) Equity Ratio (2021 - 2025)
Prime Medicine's Equity Ratio history spans 5 years, with the latest figure at 0.35 for Q4 2025.
- For Q4 2025, Equity Ratio fell 31.49% year-over-year to 0.35; the TTM value through Dec 2025 reached 0.35, down 31.49%, while the annual FY2025 figure was 0.35, 31.49% down from the prior year.
- Equity Ratio reached 0.35 in Q4 2025 per PRME's latest filing, down from 0.42 in the prior quarter.
- In the past five years, Equity Ratio ranged from a high of 0.88 in Q1 2023 to a low of 1.04 in Q3 2022.
- Average Equity Ratio over 5 years is 0.43, with a median of 0.57 recorded in 2024.
- Peak YoY movement for Equity Ratio: skyrocketed 269.58% in 2022, then plummeted 71.18% in 2025.
- A 5-year view of Equity Ratio shows it stood at 0.52 in 2021, then surged by 269.58% to 0.88 in 2022, then decreased by 21.79% to 0.69 in 2023, then fell by 25.01% to 0.51 in 2024, then plummeted by 31.49% to 0.35 in 2025.
- Per Business Quant, the three most recent readings for PRME's Equity Ratio are 0.35 (Q4 2025), 0.42 (Q3 2025), and 0.22 (Q2 2025).